-
Resource CategoriesTypes
Government of Canada
This data blog presents information about stigma and discrimination in people who inject drugs in Canada (Phase 5 Tracks survey, 2024)
-
Resource CategoriesTypes
CATIE
-
Resource CategoriesTypes
CTN+
This document was created by the CTN+ Community Leadership Team to ensure transparency and support community members in making informed decisions about their involvement with CTN+ work.
-
Types
Network of Networks
Clinical trials play a pivotal role in advancing medical research and shaping the future of healthcare by evaluating the safety and efficacy of new treatments andinterventions. However, ensuring diverse participation in these trials is essential to truly understand how treatments work across different populations. By includingindividuals from diverse backgrounds, including various racial, ethnic, socioeconomic, and…
-
Resource CategoriesTypes
CIHR
If patient-oriented research is intended to focus on priorities that are important to patients and produce information that is truly taken up and used to improve health care practice, therapies and policies, a strong foundation for ensuring successful collaboration must be laid
-
Resource CategoriesTypes
Patient Engagement Management Suite
This How-to Guide has been developed for anyone who needs to be involved in the implementation of Patient Engagement in the design of a clinical trial protocol.
-
Resource CategoriesTypes
Pauktuutit
The Community Readiness Model is a tool that can help communities determine how ready they are to deal with a specific issue. This project aimed to adapt, pre-test and use the CRM to identify how ready three communities (Arviat, Clyde River and Kugluktuk) are to deal with HIV.
-
Resource CategoriesTypes
US National Institute of Allergy & Infectious Diseases (NIAID)
This guide includes language suggestions for communicating about HIV and related topics. While it was originally designed to help NIAID staff communicate with empowering rather than stigmatizing language, especially as it relates to HIV, it was quickly recognized that it has value beyond NIAID.